Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger

Inflammatory Bowel Diseases

Volumn 14, Issue 6, 2008, Pages 750-755

  Grossman, Andrew B ^a,b   Noble, Angela J ^a   Mamula, Petar ^a   Baldassano, Robert N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

6 mercaptopurine; Azathioprine; Dose escalation; Immunomodulator; Pediatric

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE;

ABNORMAL LABORATORY RESULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COLITIS; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HEPATITIS; HUMAN; LEUKOPENIA; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AGE FACTORS; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 46049093818     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20387     Document Type: Article

References (24)

1. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
2. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
3. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000:CD000545.
4. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717-722.
5. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115:813-821.
6. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
7. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743.
8. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
9. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118(2 Suppl 1):S68-82.
10. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
11. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
12. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
13. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:339-345.
14. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
15. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
16. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
17. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001;48:591-592.
18. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416-421.
19. Shepanski MA, Markowitz JE, Mamula P, et al. Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original? J Pediatr Gastroenterol Nutr. 2004;39:68-72.
20. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
21. Morales A, Salguti S, Chuan L, et al. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:380-385.
22. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14:1009-1014.
23. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92:3569-3577.
24. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030.